CD19 and B-cell non-Hodgkin lymphoma: <h4>Background</h4>CD19-targeted chimeric antigen receptor-T cell (CART19) therapy is clinically effective in patients with relapsed or refractory B-cell lymphoma (BCL), but treatment failure and recurrence need to be overcome.